How much does a box of Ishazomi/Enleri cost? 2025 new price and price/performance analysis

As a new drug for the treatment of multiple myeloma, Ixazomib has been launched in China and is included in Class B medical insurance, allowing patients to enjoy a certain degree of financial support when receiving treatment. According to the current market situation, common capsule preparation specifications include 4mg, 3mg and 2.5mg. The price of each box is approximately more than 10,000 yuan, which undoubtedly makes the cost of obtaining the drug higher, especially for some patients with limited economic conditions, which may cause a certain burden.

As demand for the drug ixazomib continues to increase, pricing differences in overseas markets have also raised concerns. Overseas, the price of original drugs may reach more than 10,000 US dollars. This high price has forced many patients to give up this treatment option. In comparison, generic drugs in some countries or regions, such as 4mg ixazomib produced by Laos Pharmaceutical Factory, may cost less than 1,000 yuan per box, which is undoubtedly a more attractive option for patients who require long-term treatment.

From a cost-effective perspective, although domestic original drugs have quality assurance and better clinical data support, their high prices make them unaffordable for some patients. Imported drugs are not only expensive, but may also face instability in the drug supply chain, especially when global medical resources are tight. In addition, although generic drugs are cheap, patients need to pay attention to the reputation of the manufacturer and the production standards of the drug when choosing to ensure safety and effectiveness.

Overall, there are obvious differences in the pricing of ixazomib in domestic and foreign markets, which requires patients to comprehensively consider price, efficacy and their own economic status when choosing a drug. In the future, with the entry of more competitors and the gradual improvement of policies, the market price of ixazomib may be adjusted, thus improving its accessibility.

Reference materials:https://www.ninlaro.com/